Initially characterized as a leprosy vaccine, genome screening revealed that MIP shares a vast repertoire of highly antigenic PE/PPE proteins with Mtb (46), indicating its potency as a TB vaccine candidate. The gene discussed is MIP; the disease is tuberculosis.